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Abstract Using the keywords ‘‘urolithiasis and citrate
treatment’’, ‘‘nephrolithaisis and citrate treatment’’,
‘‘kidney stones and citrate treatment’’, a Medline search
revealed 635 articles published between 1 January 1966
and 1 December 2004. For the present analysis, only
studies meeting all of the following criteria were in-
cluded: (1) publications in English or German, (2)
studies on preventive alkali citrate treatment in patients
with calcium oxalate, uric acid and infection stone dis-
ease, (3) clinical studies including at least ten subjects,
and (4) treatment phases of at least 1 week duration. A
total of 43 studies met the inclusion criteria and were
further subclassiﬁed according to intermediate or ulti-
mate endpoints as well as to study design. With stone
recurrence as the ultimate endpoint, 21 uncontrolled
studies in almost 1,000 patients demonstrated a reduc-
tion in stone forming rate by 47–100%. In four ran-
domized controlled trials including 227 patients, 53.5%
on alkali citrate vs 35% on placebo remained stone-free
after at least 1 year of treatment (P<0.0005). Similar
values (66% vs 27.5% for alkali citrate vs placebo,
P<0.0005) were obtained in 104 patients from two
randomized trials with dissolution/clearance of residual
stones as endpoint. Unfortunately, up to 48% of alkali
citrate treated patients left the studies prematurely, pri-
marily due to adverse eﬀects such as eructation, bloat-
ing, gaseousness or frank diarrhea.
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Introduction
Citrate retards the crystallization of stone-forming
calcium salts in urine [1] and mediates the inhibitory
eﬀects of macromolecular modulators of calcium
oxalate crystallization [2, 3]. Therefore, low urinary
citrate (hypocitraturia) is a pathogenetically important
risk factor for calcium nephrolithiasis [1] which occurs
in 20–60% of calcium stone formers [4]. Incomplete
renal tubular acidosis is the most prevalent pathogenic
factor causing hypocitraturia [5]; other conditions
associated with low urinary citrate are dietary acid
load, reduced intake of vegetable ﬁbres, low urine
volume, hypokalemia, thiazide diuretics and acetazol-
amide [4, 5].
Changes in intracellular acid-base homeostasis are
the predominant determinants of proximal tubular
reabsorption and urinary excretion of citrate [4, 5, 6].
Acid loads favor tubular reabsorption of citrate and
thus hypocitraturia, whereas alkali loads reduce
tubular reabsorption and increase urinary citrate
excretion [4, 5. 6]. Indeed, urinary citrate is positively
related to net gastrointestinal absorption of alkali [1].
Therefore, treatment with alkali, usually in the form
of potassium citrate or magnesium potassium citrate,
is widely used to increase urinary citrate and reduce
rates of stone formation in patients with hypocitratu-
ric calcium nephrolithiasis [1, 4]. In addition, due to
its alkalinizing eﬀect, alkali citrate has successfully
been used to raise urine pH and reduce rates of stone
formation in patients with uric acid stones [4]. More-
over, initiation of urease induced crystallization in
urines of healthy volunteers taking oral potassium
citrate is markedly delayed [7], suggesting that alkali
citrate treatment could also be beneﬁcial in infection
stone disease.
The purpose of this paper is to critically review
available clinical studies on alkali citrate treatment
of calcium, uric acid and infection stone disease in
adults.
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Materials and methods
Selection of published studies
A Medline search for articles on the treatment of
nephrolithiasis with alkali citrate published between 1
January 1966, and 1 December 2004 was performed. We
used the key words ‘‘urolithiasis and citrate treatment’’,
‘‘nephrolithaisis and citrate treatment’’, ‘‘kidney stones
and citrate treatment’’, respectively, and found 635
published papers. For the present review, we included
articles meeting all of the criteria listed in Table 1. Ex-
cluded were all reviews, case reports, studies in children
(<18 years), physiologic/clinical studies including only
healthy volunteers, and articles in other languages than
English or German.
According to the endpoints stated in the published
articles, studies were ﬁrst classiﬁed into those with
‘‘weak’’ (intermediate) and those with ‘‘hard’’ (ultimate)
endpoints. ‘‘Weak’’ endpoints are deﬁned as changes in
urinary chemistry and/or urinary supersaturation,
whereas changes in rates of stone recurrence or rates of
dissolution/clearance of preexisting (residual) stones are
considered ‘‘hard’’ endpoints.
In addition, we categorized all articles according to
the study design, as originally presented by Churchill [7]:
1. One-group design: no comparison group, clinical
outcome measures before and during intervention in
the same individuals.
2. One-group design with a non-equivalent, i.e. not
randomly allocated comparison group, with clinical
outcome measures before and during intervention.
3. Randomized controlled trial (RCT).
Thus, all articles were ﬁrst categorized according to
their ‘‘hard’’ or ‘‘weak’’ endpoints. Thereafter, they were
subdivided according to study design: for instance, a
RTC with stone recurrence rate as ultimate endpoint
was labelled as ‘‘hard end-point, RCT on stone recur-
rence rate’’, and a non-randomized study of treatment
eﬀects on urine chemistries, where patients serve as their
own controls, was catagorized as ‘‘weak endpoint, one-
group design’’.
Statistics
Success rates and frequencies of side eﬀects of placebo
and alkali citrate treatments in randomized trials were
compared by using v2 statistics.
Results
Among the 635 published articles, we found 43 meeting
our predeﬁned criteria [9–51]. Thirty articles (70%) fo-
cused on ‘‘hard’’ and 13 on ‘‘weak’’ endpoints. Figures 1
and 2 depict the subclassiﬁcation of all studies with
‘‘hard’’ and ‘‘weak’’ end-points, respectively. Out of all
43 studies, only eight (19%) were carried out as ran-
domized controlled trials, six with ‘‘hard’’ [35, 37, 39, 41,
47, 48] and two [29, 33] with ‘‘weak’’ endpoints. The
following analysis mainly focuses on studies with ‘‘hard’’
end-points, with the primary emphasis on randomized
controlled trials.
Studies with stone recurrence rate as ‘‘hard’’ endpoint
Studies with one-group design
In 16 prospective studies [13, 14, 16, 17, 19, 20, 21, 23,
24, 26, 31, 36, 40, 43, 48, 49] lasting between 1 and
4.4 years, a total of 777 patients (groups of ten to 134)
served as their own historical controls. The daily
administered dose of alkali citrate ranged from 35 to
109 mEq. During this treatment, stone forming rates
were reduced by between 47 and 99% of pretreatment
values.
Studies with one-group design and non-equivalent
comparison groups
In ﬁve mainly retrospective studies [18, 34, 39, 44, 50],
alkali citrate treatment was administered to a total of
208 stone formers, divided into alkali citrate-treated
patients and comparison groups of non-equivalent stone
formers. These studies lasted between 1.5 and 7 years.
The daily administered dose of alkali citrate, as far as it
can be determined from the published data, ranged from
Fig. 1 Summary of the number of studies in nephrolithiasis
demonstrating a treatment eﬀect of alkali citrate on ‘‘hard’’
(ultimate) endpoints. RCT: randomized controlled trial; 1G-NEC:
study with one-group design and non-equivalent comparison
group; 1G: study with one-group design (patients serve as their
own controls)
Table 1 Inclusion criteria for the analysis of articles published on
the treatment of nephrolithiasis with alkali citrate
Alkali citrate literature review—inclusion criteria
Publications in English or German
Studies on preventive alkali citrate treatment in patients
with calcium oxalate, uric acid and infection stone disease
Clinical studies including at least ten subjects
Treatment phases of at least 1 week duration
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33 to 90 mEq. This resulted in reductions of stone
forming rates of between 62 and 100%.
RCTs on stone recurrence rates
Four RCTs [35, 37, 41, 47] on stone recurrence rates
have been published. They all focus on treatment of
calcium nephrolithiasis with alkali citrate vs placebo or
‘‘general prophylaxis’’ in unselected calcium stone pa-
tients or patients with hypocitraturic calcium nephro-
lithiasis. Whereas three studies [35, 37, 41] exclusively
report on stone recurrence rates, the article by Soygu¨r
et al. [47] is somewhat special in that: (1) 20 out of 110
calcium stone patients after stone treatment were ex-
cluded for various reasons before randomization to
treatments took place, and (2) it included both stone-free
patients and patients with residual stones after ESWL.
For the present discussion, we only included those 56
patients who were stone-free at randomization into the
study [47].
Table 2 summarizes the four RCTs lasting either 12
[47] or 36 months [35, 37, 41]. It is remarkable that all
current sound evidence on the therapeutic eﬀect of alkali
citrate is derived from only 227 randomly treated pa-
tients! The daily administered dose of alkali citrate in the
four studies amounted to 60–90 mEq. When analyzing
the four studies on an intention-to-treat basis, 53.5% of
alkali citrate treated patients remained stone-free after at
least 1 year of treatment, signiﬁcantly more than on
placebo (35%, P<0.0005 vs alkali citrate). Our overall
stone-free percentage of 53.5% on citrate treatment
clearly contrasts with the 72% and 87% of stone-free
patients published by Barcelo et al. [35] and Ettinger
et al. [41]. However, their calculations were based on
patients who actually ﬁnished the study, not on an
intention-to-treat analysis. Also of note is the fact that
17% of subjects in the placebo, but 30% in the alkali
citrate group (P<0.0005 vs placebo) prematurely
dropped out after randomization; the highest drop-out
rate of 48% was observed on potassium magnesium ci-
trate treatment in the study by Ettinger et al. [41]. Except
for patients’ non-compliance, drop-outs were primarily
due to adverse eﬀects such as eructation/bloating/gas-
eousness (26%) or diarrhea (12%) [41].
Studies with stone/fragment dissolution or clearance
as ‘‘hard’’ endpoint
Studies with one-group design
Three studies [9, 10, 11] report on alkali citrate treatment
of uric acid stones. A total of 216 patients were studied
for up to 5 years and served as their own historical
controls. The percentage of stone-free patients during
treatment ranged from 62 to 83%.
Studies with one-group design and non-equivalent
comparison groups
No such studies on stone dissolution or clearance are
available.
RCTs on stone/fragment dissolution or clearance
Published data on stone/fragment dissolution or clear-
ance could be gathered from three published studies [38,
46, 47]. However, we could not include the data from
Premgamone et al. [46] into our analysis, since this study
reported only on stone size reduction over time, as
measured by repeated ultrasound examination, but did
not mention numbers of stone-free patients. Further-
more, the study was not placebo-controlled, since pa-
tients were randomized to either sodium potassium
citrate or a tea based on the herbal plant Orthosiphus
grandiﬂorus which is known to increase urinary citrate
excretion [46].
Fig. 2 Summary of the number of studies in nephrolithiasis
demonstrating a treatment eﬀect of alkali citrate on ‘‘weak’’
(intermediate) endpoints
Table 2 Summary of
randomized controlled trials on
the eﬀects of alkali citrate
treatment on stone recurrence
rate as a ‘‘hard’’ (ultimate)
endpoint. *P<0.0005 vs
placebo, + drop-outs excluded
before randomization to
treatment [47]
First author Barcelo Hofbauer Ettinger Soygu¨r Total
(Reference no.) [35] [37] [41] [48]
Started Placebo 29 25 33 28 115
Alkali citrate 28 25 31 28 112
Drop-outs Placebo 9 3 8 0+ 20
Alkali citrate 10 9 15 0+ 34*
Finished Placebo 20 22 25 28 95
Alkali citrate 18 16 16 28 78
No new
stones
Placebo 9 6 9 20 44
Alkali citrate 14 5 14 28 61*
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For our analysis of RCTs on clearance/dissolution of
residual stones, we thus included the data from Cicerello
et al. [38] on alkali citrate treatment of calcium and
infection stone formers with residual stones as well as
the subgroup of patients with residual stones/fragments
in the study by Soygu¨r et al. [47]. Therefore, as depicted
in Table 3, a total of 104 stone patients have been ran-
domly studied vs placebo with stone dissolution/clear-
ance as ultimate endpoint. The daily administered dose
of alkali citrate amounted to 60–80 mEq. When ana-
lyzing the data on an intention-to-treat basis, 66% of
alkali citrate-treated patients became stone-free after
1 year of treatment, signiﬁcantly more than in the pla-
cebo group (27.5%, P<0.0005 vs alkali citrate). Drop-
outs were very rare; however, this ﬁnding is inﬂuenced
by the fact that Soygu¨r et al. [47] excluded 20 stone
patients for various reasons before randomization took
place.
Studies with ‘‘weak’’ endpoints
Studies with one-group design
Ten short-term studies [12, 15, 22, 25, 27, 28, 30, 32, 42,
45] report on alkali citrate treatment of calcium or uric
acid stone formers. A total of 313 patients were studied
for between 1 and 12 weeks. As far as mentioned in the
studies, urine pH increased by between 1% and 14%
from pretreatment values. The same was true for urinary
citrate which increased by between 27% and 94%.
Urinary oxalate changed between +24.5% and 32.7%
from pretreatment values, whereas urinary calcium de-
creased by between 8% and 40% in all studies except
one in which an increase by 15.4% was noted on com-
bined magnesium citrate/magnesium oxide treatment
[25]. In some studies, changes in relative urinary super-
saturations (calculated as formation product ratios)
from baseline values were reported; they ranged from
+5% [26] to 49% [15] for calcium oxalate and from
24% [25] to +67% [22] for calcium phosphate, indi-
cating trends for reduced calcium oxalate and for
increased calcium phosphate supersaturations on alkali
citrate treatment.
Study with one-group design and non-equivalent
comparison group
There is only one recent study [51] reporting 61 stone
patients treated for 1 month in four treatment sub-
groups: (1) potassium chloride, (2) potassium sodium
citrate, (3) magnesium glycine, and (4) potassium mag-
nesium citrate (63 mEq/day). Urine pH and citrate sig-
niﬁcantly increased only in patients treated with either
potassium citrate or potassium magnesium citrate,
whereas potassium chloride and magnesium glycine in-
duced a fall in urine pH without a change in citraturia.
The latter clearly increased urinary supersaturation of
uric acid, whereas all four supplements left calcium
oxalate supersaturation unchanged [51].
RCTs
Two RCTs have been reported [29, 33], both short-term
studies lasting 1 week. Pak et al. [29] sequentially studied
ﬁve normal subjects and ﬁve calcium stone formers
during a placebo phase as well as during treatments with
potassium citrate (50 mEq/day) and potassium magne-
sium citrate (73.5 mEq citrate/day). In comparison with
placebo, potassium magnesium citrate induced more
pronounced increases in urinary citrate and pH than
potassium citrate. This was accompanied by a greater
decline in the amount of daily excreted undissociated
uric acid and a more pronounced increase in urinary
citrate excretion. Consequently, the activity product of
calcium oxalate declined signiﬁcantly more during
potassium magnesium citrate (from 1.49·108 to
1.03·108 mol2) than during potassium citrate therapy
(to 1.14·108 mol2) [29].
Using a similar trial design, Wabner and Pak [33]
studied eight healthy men and three hypocitraturic cal-
cium stone formers in three phases, each lasting 1 week.
Compared with placebo, 1.2 l of orange juice per day
(190 mEq citrate) and potassium citrate (60 mEq/day)
caused similar increases in urine pH and citrate. This
was associated with comparable decreases in urinary
undissociated uric acid levels. On the other hand, be-
cause orange juice increased urinary oxalate without
changing urinary calcium, only potassium citrate sig-
niﬁcantly reduced urinary saturation of calcium oxalate
[33].
Discussion
Success or failure of any medical treatment is ascer-
tained by the comparison of outcomes in active treat-
ment and control groups. Placebo or sham control
groups are clearly preferred, although historical controls
are often used as less desirable alternatives [52]. The
Table 3 Summary of randomized controlled trials on the eﬀects of
alkali citrate treatment on clearance or dissolution of residual
stones/fragments as a ‘‘hard’’ (ultimate) endpoint. * P<0.0005 vs
placebo, + drop-outs excluded before randomization to treatment
[47]
First author Cicerello Soygu¨r Total
(Reference No.) [38] [48]
Started Placebo 35 16 51
Alkali citrate 35 18 53
Drop-outs Placebo 1 0+ 1
Alkali citrate 1 0+ 1
Finished Placebo 34 16 50
Alkali citrate 34 18 52
Stone-free Placebo 12 2 14
Alkali citrate 27 8 35*
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main ﬁnding of the present literature review is that alkali
citrate treatment of nephrolithiasis has been investigated
in a prospective randomized manner in only 352 subjects
in eight studies [29, 33, 35, 37, 39, 41, 47, 48]. When
solely considering studies with ‘‘hard’’ (ultimate) end-
points, the respective number falls to 331 stone formers,
studied with either stone recurrence rate (227 patients)
or dissolution/clearance of residual stones (104 patients)
as endpoints. This is rather surprising, given the fact that
prevalences of nephrolithiasis are increasing and now
reach 11.7% in Europe [53] and 11.1% in the US [54] in
men in their mid-sixties; respective values for women are
7.7% [53] and 5.6% [54].
The uncontrolled studies with ‘‘weak’’ (intermediate)
endpoints included in our analysis suﬀer from a wide
variability in study design. Nevertheless, they generally
reveal what can theoretically be expected, namely that
urine pH and citrate increase in patients treated with
either potassium citrate or potassium magnesium citrate.
Altogether, data from 374 subjects treated for between 1
and 12 weeks demonstrate increases in urine pH of up to
14% and in urinary citrate of up to 94% from pre-
treatment values. This is generally accompanied by de-
creases in urinary calcium oxalate supersaturation of up
to 49%, but increases in calcium phosphate supersatu-
ration of up to 67% may occur.
Consequently, 21 uncontrolled studies with stone
recurrence as ‘‘hard’’ (ultimate) endpoint [13, 14, 16, 17,
18, 19, 20, 21, 23, 24, 26, 31, 34, 36, 39, 40, 43, 44, 48, 49,
50] in almost 1,000 patients have demonstrated that
stone forming rate was reduced by between 47% and
100% of pretreatment values. Four randomized con-
trolled trials including 227 patients, when analyzed on
an intention-to-treat basis, also reveal that more than
half of all alkali citrate treated patients remain stone-free
after at least 1 year of treatment, signiﬁcantly more than
on placebo treatment (35%). Of at least equal impor-
tance appear data from two randomized, placebo-con-
trolled trials with clearance or dissolution of preexisting
(residual) stones as ultimate endpoint. After 1 year of
treatment, 66% of alkali citrate-treated patients became
stone-free, again signiﬁcantly more than on placebo
(27.5%). This may appear highly relevant for thousands
of patients undergoing shock-wave lithotripsy who
might proﬁt from routine administration of alkali citrate
for improved clearance of residual fragments. Indeed, it
can be anticipated that more complete fragment clear-
ance would be associated with a reduced likelihood of
residual fragments becoming niduses for newly growing
stones.
The overall percentage of stone-free patients (53.5%)
on alkali citrate in the present analysis of published
studies with stone recurrence as endpoint contrasts with
considerably higher numbers of 72% and 87% in some
of the studies [35, 41]. However, these latter calculations
were based on patients who actually ﬁnished the studies,
whereas we strongly believe that a more realistic sum-
mary should strictly be based on an intention-to-treat
analysis (Table 2). Unfortunately, we were not able to
perform a thorough intention-to-treat analysis of all
published data, since some patients were excluded before
randomization to alkali citrate or placebo in one study
[47].
Alkali citrate treatment not only raises urinary citrate
levels in patients with calcium nephrolithiasis [1, 4], but
also has a general alkalinizing eﬀect which is beneﬁcial
for patients with uric acid [4] as well as cystine stones
[55]. Moreover, alkali citrate may even be beneﬁcial for
retarding the growth of infection stones [7]. Therefore,
alkali citrate could be a sort of panacea for almost any
kind of kidney stone disease. As obvious from the
present review, a main limitation for more widespread
use of alkali citrate preparations is the relatively low
tolerability of available alkali citrate preparations.
Overall, 17% of subjects on placebo, but almost one
third on alkali citrate treatment for prevention of stone
recurrences, prematurely left randomized trials. It is
noteworthy that the highest ever reported drop-out rate,
almost half of the patients, was observed on treatment
with potassium magnesium citrate [41], which basically
appears to be more eﬃcient than potassium citrate in
lowering the activity product of calcium oxalate [29].
Adverse eﬀects that reduce treatment compliance have
been noted mainly in the gastrointestinal tract and in-
clude eructation, bloating or gaseousness in 26% and
frank diarrhea in 12% of potassium magnesium citrate
treated patients [41]. Thus, the development of better
tolerated alkali citrate preparations remains an impor-
tant issue for the future.
The fact that any alkali would suﬃce to increase
urinary pH and citrate [4] could oﬀer interesting alter-
natives for stone patients who do not tolerate currently
available alkali citrate preparations. As observed by
Wabner and Pak [33], 1.2 l of orange juice per day cause
increases in urine pH and citrate similar to a conven-
tional dose of potassium citrate. More recently, Kessler
and Hesse [56] studied 24 healthy male volunteers and
observed that bicarbonate-rich mineral water, adminis-
tered in equimolar concentrations with respect to the
amount of delivered alkali, was equally eﬀective to so-
dium potassium citrate in increasing urine pH and cit-
rate as well as decreasing relative urinary
supersaturations of calcium oxalate and uric acid. Fi-
nally, Premgamone et al. [46] reported equal stone size
reductions over time in stone formers randomized to
either sodium potassium citrate or a tea based on the
herbal plant O. grandiﬂorus which is known to increase
urinary citrate. Remarkably, alkali citrate induced ad-
verse eﬀects in 26% of patients, whereas stone formers
treated with the herbal tea did not experience adverse
eﬀects at all [46]. In summary, many patients who do not
tolerate alkali citrate medications might proﬁt from such
more ‘‘natural’’ sources of alkali.
In conclusion, our literature review conﬁrms that al-
kali citrate has a signiﬁcant eﬀect not only on urine
chemistries and supersaturation levels, but more
importantly also reduces the incidence of stone recur-
rences. Furthermore, rates of clearance or dissolution of
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preexisting stones or fragments are signiﬁcantly im-
proved, which may call for routine treatment with alkali
citrate in all patients undergoing shock-wave lithotripsy.
Finally, for those patients who do not tolerate alkali
citrate preparations, suﬃcient amounts of bicarbonate-
rich mineral water, orange juice or a herbal tea based on
O. grandiﬂorus appear to be valuable alternatives.
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